Evidence map›Paper›PMID 26755624›Full record

ArticleBioinformatics (Oxford, England)2016

Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.

Jonathan H Young, Michael Peyton, Hyun Seok Kim, Elizabeth McMillan, John D Minna, Michael A White, Edward M Marcotte

Open access · hybridAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jonathan H YoungInstitute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA, Center for Systems and Synthetic Biology and Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Michael PeytonHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hyun Seok KimSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea, and.
Elizabeth McMillanDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
John D MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Michael A WhiteDepartment of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Edward M MarcotteInstitute for Computational Engineering and Sciences, University of Texas at Austin, Austin, TX, USA, Center for Systems and Synthetic Biology and Department of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
The University of Texas Southwestern Medical Center · USThe University of Texas at Austin · USYonsei University · KR

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
DIVISION OF CELL &MOLECULAR BIOLOGY TRAINING PROGRAMT32GM008203 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI COBB, MELANIE H. · 1987 to 2018
$7.0M
Next-Generation Proteomics: Massively Parallel Single-Molecule Protein IdentificaDP1GM106408 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI MARCOTTE, EDWARD M · 2012 to 2016
$3.8M
Lung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8M
Targeting Mechanistic Subtypes of Neoplastic DiseaseR35CA197717 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WHITE, MICHAEL A. · 2015 to 2015
$725k
NCI NIH HHS P50 CA070907NCI NIH HHS R35 CA197717NCI NIH HHS U01 CA176284NIGMS NIH HHS DP1 GM106408NIGMS NIH HHS T32 GM008203
6 · The paper itself

Abstract

motivationNovel approaches are needed for discovery of targeted therapies for non-small-cell lung cancer (NSCLC) that are specific to certain patients. Whole genome RNAi screening of lung cancer cell lines provides an ideal source for determining candidate drug targets.

resultsUnsupervised learning algorithms uncovered patterns of differential vulnerability across lung cancer cell lines to loss of functionally related genes. Such genetic vulnerabilities represent candidate targets for therapy and are found to be involved in splicing, translation and protein folding. In particular, many NSCLC cell lines were especially sensitive to the loss of components of the LSm2-8 protein complex or the CCT/TRiC chaperonin. Different vulnerabilities were also found for different cell line subgroups. Furthermore, the predicted vulnerability of a single adenocarcinoma cell line to loss of the Wnt pathway was experimentally validated with screening of small-molecule Wnt inhibitors against an extensive cell line panel. AVAILABILITY AND IMPLEMENTATION: The clustering algorithm is implemented in Python and is freely available at https://bitbucket.org/youngjh/nsclc_paper CONTACT: marcotte@icmb.utexas.edu or jon.young@utexas.edu SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

DNA, NeoplasmAlgorithmsCarcinoma, Non-Small-Cell LungCluster AnalysisGene Expression Regulation, NeoplasticHumansLung NeoplasmsDNA, Neoplasm

Identifiers

PMID26755624
PMCPMC4848405
OpenAlexW2278260636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.